Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23872392 | 0.93 | DNM1 (0.41) | MEN1KMT2ATP53DNM1CA2 | |
| SCHEMBL24571657 | 0.86 | CA1 (0.40) | CA1CA2CA12 | |
| SCHEMBL24571565 | 0.85 | TSHR (0.36) | CA1CA2MAPT | |
| SCHEMBL12448155 | 0.82 | ALDH1A1 (0.38) | DNM1CA2CA12CA9 | |
| SCHEMBL25927628 | 0.80 | LMNA (0.32) | — | |
| SCHEMBL13100465 | 0.79 | TP53 (0.39) | TP53TDP1CA1CA2CA12 | |
| SCHEMBL19869629 | 0.76 | CA12 (0.35) | CA2CA12CA9 | |
| SCHEMBL13100466 | 0.76 | KDM4E (0.39) | TP53TDP1CA1CA2CA12 | |
| SCHEMBL13301125 | 0.75 | — | — | |
| SCHEMBL16090593 | 0.75 | MEN1 (0.42) | MEN1KMT2ATDP1DNM1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9428473-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160002186-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2016-01-07 | — | — | US | disclosed |
| US-9115100-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8853210-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-8497396-B2 | Methods and intermediates for preparing pharmaceutical agents | GILEAD SCIENCES, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | GILEAD SCIENCES, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005493-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | MEN1 366/4885KMT2A 4442/4885TP53 1358/4885 |
| US-20100256366-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | MEN1 366/4885KMT2A 4442/4885TP53 1358/4885 |
| US-20140088304-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | MEN1 366/4885KMT2A 4442/4885TP53 1358/4885 |
| US-20160002186-A1 | METHODS AND INTERMEDIATES FOR PREPARING PHARMACEUTICAL AGENTS | CYP2F1, UGT1A1, CYP3A7 | MEN1 366/4885KMT2A 4442/4885TP53 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.